Peptide-Based Therapeutics Summit on April 01-03, 2025 in Boston, United States

With Merck's oral PCSK9 inhibitor demonstrating strong phase 3 trial results, J AND J's IL23R antagonist peptide continuing its phase 3 journey, and Chugai advancing peptides into the intracellular space, peptide therapeutics are firmly back on the map as the next modality disrupting drug discovery and development.

This includes exploring peptide structure prediction using AI/ML technologies, designing orally bioavailable and cell membrane-permeable peptides using structure-based molecular design, harnessing mRNA display and DNA-encoded libraries for peptide discovery, optimizing peptide synthesis, integrating formulation considerations at the discovery stage, and investigating peptides as drug delivery vehicles.

The 2nd Peptide-Based Therapeutics Summit returns to Boston as your most comprehensive, industry-dedicated forum for overcoming the unique drug discovery challenges of peptide-based therapeutics and powering up your development pipelines to achieve 2025/26 milestones.

As this revitalized space reaches a critical tipping point, join the conversation on how advancements in computational, medicinal chemistry, and formulation technologies are driving peptide pipeline progression from hit to lead.

Use this as your pulse-check opportunity to stay abreast of peptide drug discovery news, build meaningful partnerships, and supercharge cutting-edge peptide-based therapies from concept to clinic and beyond!

URLs:

Tickets: https://go.evvnt.com/2775248-2?pid=10008

Brochure: https://go.evvnt.com/2775248-3?pid=10008

Time: 8:00 AM - 5:00 PM

Prices:

Conference + 2 Workshops - Drug Developer Pricing: USD 4197.00,

Conference + 1 Workshop - Drug Developer Pricing: USD 3598.00,

Conference Only - Drug Developer Pricing: USD 2999.00,

Conference + 2 Workshops - Solution Provider Pricing: USD 5197.00,

Conference + 1 Workshop - Solution Provider Pricing: USD 4498.00,

Conference Only - Solution Provider Pricing: USD 3799.00,

Conference + 2 Workshops - Academic Pricing: USD 3597.00,

Conference + 1 Workshop - Academic Pricing: USD 3098.00,

Conference Only - Academic Pricing: USD 2599.00

Speakers: Abbas Walji, Senior Director, Discovery Chemistry, Merck, Cameron Pye, Chief Executive Officer, Unnatural Products, Christian Cunningham, Chief Scientific Officer, PeptiDream Inc., David J. Brayden, Professor - Advanced Drug Delivery, University College Dublin, Dehua Pei, Professor of Chemistry and Biochemistry, Ohio State University, Emel Adaligil, Principal Scientific Manager, Macrocycle Discovery Group, Genentech, James Bowman, Director of Protein Engineering, AI Proteins, Jeffrey Schubert, Principal Scientist, Merck, John Tan, Director, Informatics, Nimble Therapeutics, Joshua Schwochert, Co-founder and Chief Scientific Officer, Unnatural Products, Laura Nevola, Co-Founder, Chief Scientific Officer and Chief Operating Officer, IDP Pharma, Lauren Goodrich-Berto, Vice President, Therapeutic Discovery, Nimble Therapeutics, Mah Kheirabadi, Director, Discovery Chemistry, Entrada Therapeutics Inc., Manuel Sanchez-Felix, Vice President, Drug Delivery, Halozyme Therapeutics, Markus Haeberlein, Executive Vice President - Discovery Science, Parabilis Medicines, Meritxell Teixido, CEO and Co-founder, Gate2Brain S.L., Miriam Kidron, Chief Scientific Officer, Oramed Pharmaceuticals, Patrick Salveson, Co-Founder and Chief Technology Officer, Vilya, Pete Gough, Chief Scientific Officer, Nimble Therapeutics, Ranganath Gopalakrishnan, Director, New Modalities Medicinal Chemistry, Early CVRM, AstraZeneca, Rick Ewing, Vice President and Head of Chemistry, Rapafusyn Pharmaceuticals, Robert Maguire, Director of Chemistry, Cybrexa Therapeutics, Sevan Habeshian, Co-founder and Chief Technology Officer, Orbis Medicines, Thomas Von Erlach, Co-Founder and Chief Scientific Officer, Vivtex, Toby Passioura, Co-Founder and Chief Scientific Officer, Insamo, Tomi Sawyer, Chief Drug Hunter and President, Maestro Therapeutics, Xavier Michelet, Director of Biology, AI Proteins, Yoshihisa Murata, Head of Advanced Computational Chemistry Group, Chugai Pharmaceutical Co, Yu-Shan, Lin Professor and Department Chair of Chemistry, Tufts University